Arrowhead Q3 Loss Wider Than Expected, but REDEMPLO Sales Double and Pipeline Advances
ARWR has more than doubled off its 52-week low of $15.01.
Summary
Arrowhead reported a wider-than-expected Q3 loss, but REDEMPLO sales doubled and plozasiran pivotal data was stellar. The company acquired a Priority Review Voucher and ended the quarter with $1.6 billion in cash and investments.
Key Events · Earnings and Guidance · ARWR
-
Q3 Loss Wider Than Expected
Net loss of $194.3 million, or $1.36 per share, compared to a loss of $175.2 million, or $1.26 per share, in the prior-year quarter. Revenue rose to $75.3 million from $27.8 million, driven by collaboration agreements.
-
REDEMPLO Sales Double
Commercial product revenue not separately disclosed, but management noted REDEMPLO sales doubled, reflecting strong launch uptake in FCS.
-
Plozasiran Pivotal Data Stellar
Phase 3 SHASTA-3 and SHASTA-4 trials met all endpoints, with median triglyceride reductions of 79% and 81%, and a 78% reduction in acute pancreatitis events. A supplemental NDA for sHTG is planned, supported by a newly acquired Priority Review Voucher.
-
Pipeline Advances with New Partnerships
Madrigal licensed ARO-PNPLA3 for $25 million upfront and up to $975 million in milestones. Novartis collaboration generated $20.2 million in revenue. Sarepta collaboration contributed $26.4 million.
Analysis · ARWR · Life Sciences
Arrowhead's Q3 loss of $1.36 per share missed expectations, but the quarter was packed with positive pipeline and commercial developments. REDEMPLO sales doubled, plozasiran's pivotal data was stellar, and the company acquired a Priority Review Voucher to speed its sHTG filing. The balance sheet remains strong with $1.6 billion in cash and investments, bolstered by a $700 million convertible note offering and equity raises. Operating expenses are rising as the pipeline advances, but collaboration revenue from Sarepta, Novartis, and Madrigal provides non-dilutive funding. The quarter underscores Arrowhead's transition to a commercial-stage biotech with a deep pipeline and multiple shots on goal.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.5% of the 993 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.86%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARWR was trading at $90.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $15.01 to $95.49. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.